ANXIETY (GAD) · White paper
Generalized Anxiety Disorder (GAD) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About generalized anxiety disorder (gad) — and why its trials are hard
Generalized Anxiety Disorder (GAD) is a chronic, disabling condition defined by excessive, uncontrollable worry occurring more days than not for at least six months, coded 6A71 in ICD-11 and 300.02 (F41.1) in DSM-5. Once dismissed as ordinary stress, it is now recognized as a serious neuropsychiatric disorder tied to serotonergic and GABAergic dysregulation, with heritability around 30%. The approved pharmacologic armamentarium is dominated by the azapirone buspirone and by serotonergic antidepressants: SSRIs paroxetine and escitalopram and SNRIs venlafaxine and duloxetine. Efficacy in registration trials is typically measured by change in the Hamilton Anxiety Rating Scale (HAM-A) and response/remission rates. Drug development is hampered by a large and variable placebo response, subjective outcome measures, heterogeneous patient populations, and the difficulty of targeting GAD's poorly understood pathophysiology. Several candidates, including tofisopam, gepirone ER, and the GABA-A modulator PF-06372865, failed on efficacy or safety, and pregabalin, approved in Europe, was denied US approval for GAD.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Buspirone (BuSpar) | 1986 | Non-benzodiazepine azapirone anxiolytic; 5-HT1A partial agonist | Placebo-controlled anxiety trials | Hamilton Anxiety Rating Scale (HAM-A) | Significant HAM-A reduction vs placebo without benzodiazepine dependence |
| Paroxetine (Paxil) | 2001 | SSRI approved for GAD, especially with comorbid depression | Pivotal 8-week placebo-controlled GAD trials | Change in HAM-A total score; response rate | Significantly higher response/remission rates than placebo |
| Escitalopram (Lexapro) | 2003 | SSRI approved for GAD and major depressive disorder | Pooled placebo-controlled GAD trials | Change in HAM-A total score | Significant HAM-A improvement vs placebo (approved for GAD in 2003; unverified exact effect size) |
| Venlafaxine (extended-release) (Effexor XR) | 1999 | First SNRI approved for GAD; also treats depression and panic disorder | Long-term placebo-controlled XR trials (up to 6 months) | Change in HAM-A; sustained response | Significant and sustained HAM-A reduction vs placebo over 6 months |
| Duloxetine (Cymbalta) | 2007 | SNRI approved for GAD, MDD, and neuropathic pain | Pivotal placebo-controlled GAD trials | Change in HAM-A total score | Significant improvement vs placebo across pivotal trials |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in generalized anxiety disorder (gad) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Pregabalin — US GAD monotherapy program (Lyrica) | Received an FDA Complete Response Letter; never approved for GAD in the US despite EU approval | Regulatory/efficacy-consistency concerns; single-mechanism (calcium-channel) approach and placebo variability |
| Gepirone ER — GAD registration program | Did not meet primary efficacy endpoints for GAD | Insufficient separation from placebo; azapirone class efficacy limits |
| PF-06372865 — Phase 2 GAD program | Development halted for safety concerns and insufficient efficacy | GABA-A subtype modulation did not deliver an adequate benefit-risk profile |
Choosing the right endpoint
Primary endpoints that matter in generalized anxiety disorder (gad) trials
- Hamilton Anxiety Rating Scale (HAM-A) — Clinician-rated total score change is the standard primary efficacy endpoint in GAD registration trials
- Response and remission rates — Response often defined as ≥50% HAM-A reduction; remission as HAM-A ≤7-10, key secondary endpoints
- Clinical Global Impression (CGI-S/CGI-I) — Global clinician rating of severity and improvement used to corroborate scale-based change
- Sheehan Disability Scale / functional outcomes — Captures functional impairment across work, social, and family domains
- Relapse prevention (randomized withdrawal) — Long-term maintenance endpoint assessing time to relapse after stabilization
How iNGENū runs generalized anxiety disorder (gad) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Generalized Anxiety Disorder (GAD) clinical trials — FAQs
What medications are FDA-approved for GAD?
Why is the placebo response a problem in GAD trials?
What is the primary endpoint in GAD registration trials?
Ready to discuss your generalized anxiety disorder (gad) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal